NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News_老虎社区_美港股上老虎

NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News

InvestorPlace2021-12-24

The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Beli
·2021-12-27
Wow, good to hear it's effectiveness for children as well!
回复
1
举报
Jontrade
·2021-12-25
What about distribution timeline?
回复
点赞
举报
收起
- Tamashii:
  infinity!
  2021-12-26
  回复
  举报
Looyusooi
·2021-12-25
Good
回复
1
举报
saket
·2021-12-24
Like
回复
4
举报
收起
- 土金水木火:
  Done
  2021-12-24
  回复
  举报
NeM0ooo
·2021-12-24
Like
回复
5
举报
LWKJKK
·2021-12-24
Hope this will soar a new high!
回复
5
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1135530287?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-24 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135530287","market":"us","top_or_hot":-1,"title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News","media":"InvestorPlace","content":"<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","article_id":"1135530287","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","pubTimestamp":1640312913,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"NVAX股票：关于Novavax抗击奥密克戎新闻的5件事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[{"id":696064001,"gmtCreate":1640577927006,"gmtModify":1640577927148,"author":{"id":"4092138473478360","authorId":"4092138473478360","name":"Beli","avatar":"https://static.tigerbbs.com/12287da3d64d63968897c06e82fb422b","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Wow, good to hear it's effectiveness for children as well!","listText":"Wow, good to hear it's effectiveness for children as well!","text":"Wow, good to hear it's effectiveness for children as well!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696064001","repostId":1135530287,"repostType":2,"repost":{"id":"1135530287","pubTimestamp":1640312913,"share":"https://www.laohu8.com/m/news/1135530287?lang=&edition=full","pubTime":"2021-12-24 10:28","market":"us","language":"en","title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News","url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","media":"InvestorPlace","summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","content":"<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the&nbsp;dominant coronavirus strain&nbsp;in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.</p>\n<p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) recently reported the&nbsp;initial results&nbsp;of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive&nbsp;immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.</p>\n<p>Novavax’s President of Research and Development Gregory Glenn added that:</p>\n<blockquote>\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n</blockquote>\n<p>In recent Novavax news, its vaccine was&nbsp;granted approval&nbsp;for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.</p>\n<p>With the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.</p>\n<p>NVAX Stock: 5 Things to Know</p>\n<ol>\n <li>After two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.</li>\n <li>Novavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.</li>\n <li>Additionally, the vaccine maker has plans to ship 200 million doses to the E.U.</li>\n <li>Glenn remarked that “Given the continued evolution of the coronavirus, the development of an&nbsp;omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”</li>\n <li>Novavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135530287","content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":698646926,"gmtCreate":1640393625992,"gmtModify":1640393626233,"author":{"id":"4092282490520410","authorId":"4092282490520410","name":"Jontrade","avatar":"https://static.tigerbbs.com/632d9c508b5348ca40d2924a5296b754","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"What about distribution timeline?&nbsp;","listText":"What about distribution timeline?&nbsp;","text":"What about distribution timeline?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698646926","repostId":1135530287,"repostType":4,"repost":{"id":"1135530287","pubTimestamp":1640312913,"share":"https://www.laohu8.com/m/news/1135530287?lang=&edition=full","pubTime":"2021-12-24 10:28","market":"us","language":"en","title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News","url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","media":"InvestorPlace","summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","content":"<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the&nbsp;dominant coronavirus strain&nbsp;in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.</p>\n<p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) recently reported the&nbsp;initial results&nbsp;of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive&nbsp;immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.</p>\n<p>Novavax’s President of Research and Development Gregory Glenn added that:</p>\n<blockquote>\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n</blockquote>\n<p>In recent Novavax news, its vaccine was&nbsp;granted approval&nbsp;for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.</p>\n<p>With the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.</p>\n<p>NVAX Stock: 5 Things to Know</p>\n<ol>\n <li>After two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.</li>\n <li>Novavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.</li>\n <li>Additionally, the vaccine maker has plans to ship 200 million doses to the E.U.</li>\n <li>Glenn remarked that “Given the continued evolution of the coronavirus, the development of an&nbsp;omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”</li>\n <li>Novavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135530287","content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7111015,"gmtCreate":1640504317722,"gmtModify":1640504317756,"authorId":4087109479010510,"author":{"id":4087109479010510,"authorId":4087109479010510,"name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698646926,"type":1,"supId":0,"prevId":0,"content":"infinity!","text":"infinity!","html":"infinity!"}],"langContent":"CN"},{"id":698610447,"gmtCreate":1640364871143,"gmtModify":1640364871294,"author":{"id":"4100437715079400","authorId":"4100437715079400","name":"Looyusooi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698610447","repostId":1135530287,"repostType":4,"repost":{"id":"1135530287","pubTimestamp":1640312913,"share":"https://www.laohu8.com/m/news/1135530287?lang=&edition=full","pubTime":"2021-12-24 10:28","market":"us","language":"en","title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News","url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","media":"InvestorPlace","summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","content":"<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the&nbsp;dominant coronavirus strain&nbsp;in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.</p>\n<p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) recently reported the&nbsp;initial results&nbsp;of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive&nbsp;immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.</p>\n<p>Novavax’s President of Research and Development Gregory Glenn added that:</p>\n<blockquote>\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n</blockquote>\n<p>In recent Novavax news, its vaccine was&nbsp;granted approval&nbsp;for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.</p>\n<p>With the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.</p>\n<p>NVAX Stock: 5 Things to Know</p>\n<ol>\n <li>After two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.</li>\n <li>Novavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.</li>\n <li>Additionally, the vaccine maker has plans to ship 200 million doses to the E.U.</li>\n <li>Glenn remarked that “Given the continued evolution of the coronavirus, the development of an&nbsp;omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”</li>\n <li>Novavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135530287","content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":698198558,"gmtCreate":1640314078095,"gmtModify":1640314078264,"author":{"id":"4102558411634440","authorId":"4102558411634440","name":"saket","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698198558","repostId":1135530287,"repostType":4,"repost":{"id":"1135530287","pubTimestamp":1640312913,"share":"https://www.laohu8.com/m/news/1135530287?lang=&edition=full","pubTime":"2021-12-24 10:28","market":"us","language":"en","title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News","url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","media":"InvestorPlace","summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","content":"<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the&nbsp;dominant coronavirus strain&nbsp;in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.</p>\n<p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) recently reported the&nbsp;initial results&nbsp;of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive&nbsp;immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.</p>\n<p>Novavax’s President of Research and Development Gregory Glenn added that:</p>\n<blockquote>\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n</blockquote>\n<p>In recent Novavax news, its vaccine was&nbsp;granted approval&nbsp;for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.</p>\n<p>With the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.</p>\n<p>NVAX Stock: 5 Things to Know</p>\n<ol>\n <li>After two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.</li>\n <li>Novavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.</li>\n <li>Additionally, the vaccine maker has plans to ship 200 million doses to the E.U.</li>\n <li>Glenn remarked that “Given the continued evolution of the coronavirus, the development of an&nbsp;omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”</li>\n <li>Novavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135530287","content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7096158,"gmtCreate":1640314181761,"gmtModify":1640314181871,"authorId":4087537231786360,"author":{"id":4087537231786360,"authorId":4087537231786360,"name":"土金水木火","avatar":"https://static.tigerbbs.com/b569dff568eac68113202875c896b710","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":698198558,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":698104879,"gmtCreate":1640313182480,"gmtModify":1640313845837,"author":{"id":"4091976027440070","authorId":"4091976027440070","name":"NeM0ooo","avatar":"https://static.tigerbbs.com/fc945b6e362666c4cb11d3c9b09018e8","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698104879","repostId":1135530287,"repostType":4,"repost":{"id":"1135530287","pubTimestamp":1640312913,"share":"https://www.laohu8.com/m/news/1135530287?lang=&edition=full","pubTime":"2021-12-24 10:28","market":"us","language":"en","title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News","url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","media":"InvestorPlace","summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","content":"<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the&nbsp;dominant coronavirus strain&nbsp;in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.</p>\n<p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) recently reported the&nbsp;initial results&nbsp;of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive&nbsp;immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.</p>\n<p>Novavax’s President of Research and Development Gregory Glenn added that:</p>\n<blockquote>\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n</blockquote>\n<p>In recent Novavax news, its vaccine was&nbsp;granted approval&nbsp;for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.</p>\n<p>With the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.</p>\n<p>NVAX Stock: 5 Things to Know</p>\n<ol>\n <li>After two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.</li>\n <li>Novavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.</li>\n <li>Additionally, the vaccine maker has plans to ship 200 million doses to the E.U.</li>\n <li>Glenn remarked that “Given the continued evolution of the coronavirus, the development of an&nbsp;omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”</li>\n <li>Novavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135530287","content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":698105627,"gmtCreate":1640313091348,"gmtModify":1640313839641,"author":{"id":"4096337009824130","authorId":"4096337009824130","name":"LWKJKK","avatar":"https://static.tigerbbs.com/c8865fe58cb1e2421bb5f60a39a8af3e","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Hope this will soar a new high!","listText":"Hope this will soar a new high!","text":"Hope this will soar a new high!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698105627","repostId":1135530287,"repostType":2,"repost":{"id":"1135530287","pubTimestamp":1640312913,"share":"https://www.laohu8.com/m/news/1135530287?lang=&edition=full","pubTime":"2021-12-24 10:28","market":"us","language":"en","title":"NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News","url":"https://stock-news.laohu8.com/highlight/detail?id=1135530287","media":"InvestorPlace","summary":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday se","content":"<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the&nbsp;dominant coronavirus strain&nbsp;in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.</p>\n<p><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>) recently reported the&nbsp;initial results&nbsp;of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive&nbsp;immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.</p>\n<p>Novavax’s President of Research and Development Gregory Glenn added that:</p>\n<blockquote>\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n</blockquote>\n<p>In recent Novavax news, its vaccine was&nbsp;granted approval&nbsp;for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.</p>\n<p>With the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.</p>\n<p>NVAX Stock: 5 Things to Know</p>\n<ol>\n <li>After two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.</li>\n <li>Novavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.</li>\n <li>Additionally, the vaccine maker has plans to ship 200 million doses to the E.U.</li>\n <li>Glenn remarked that “Given the continued evolution of the coronavirus, the development of an&nbsp;omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”</li>\n <li>Novavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.</li>\n</ol>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVAX Stock: 5 Things to Know About Novavax’s Omicron-Fighting News\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 10:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the...</p>\n\n<a href=\"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/12/nvax-stock-5-things-to-know-about-novavaxs-omicron-fighting-news/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1135530287","content_text":"The omicron variant has shown no signs of slowing down as people prepare to celebrate the holiday season. Earlier this week, the CDC reported that omicron is now the dominant coronavirus strain in the United States, accounting for 73% of all cases. However, encouraging news from the initial results of a study has investors in a particular vaccine stock excited.\nNovavax(NASDAQ:NVAX) recently reported the initial results of its study on NVX-CoV2373, its vaccine. The vaccine demonstrated “cross-reactive immune responses against omicron as well as other variants.” However, anti-spike antibody levels against the omicron variant were significantly higher after the third dose. In other words, the latest study suggests a three-shot regimen is better. Novavax explained that a booster shot, or even a vaccine tailored to fight against omicron, would be extremely important.\nNovavax’s President of Research and Development Gregory Glenn added that:\n\n “We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants.”\n\nIn recent Novavax news, its vaccine was granted approval for adults in the European Union. The European Medicines Agency(EMA) said that data from two large studies showed the vaccine had an efficacy rate near 90%. Furthermore, Novavax’s vaccine is the fifth vaccine to win approval from the EMA. As a result, Novavax stated that it would start shipping vaccines to the EU starting in January 2022. However, the EU made no conclusions on the vaccine’s efficacy against the omicron variant.\nWith the encouraging news in mind, let’s take a deeper look into the results of the study and what it means for NVAX stock.\nNVAX Stock: 5 Things to Know\n\nAfter two doses of Novavax’s vaccine, anti-spike antibody levels against omicron saw a 61.1-fold rise. However, after a third dose (six months after the second), antibody levels against omicron increased 73.5-fold.\nNovavax is currently conducting a Phase 3 trial in the U.S. and Mexico. Results showed that the immune responses from children were 2- to 4-fold higher than the responses from adults for all variants tested.\nAdditionally, the vaccine maker has plans to ship 200 million doses to the E.U.\nGlenn remarked that “Given the continued evolution of the coronavirus, the development of an omicron vaccine could be necessary. Novavax has cloned, expressed and characterized the omicron spike protein vaccine and will soon enter the GMP-phase of production.”\nNovavax expects to begin clinical studies for an omicron-specific vaccine in January 2022.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":99,"commentSize":0,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false}}